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Introduction: Relapse after allogeneic hematopoietic stem cell transplantation in patients with myelodysplasia is a
challenging problem with limited treatment options. Attempts to induce a graft-versus-leukemia effect have been
used with limited success. In patients with myelodysplasia, sustained complete remissions have generally been
limited to patients with long-term remission after transplant and those with low numbers of marrow blasts.
Case presentation: We report the case of a 41-year-old Caucasian woman with relapsed myelodysplastic
syndrome and a high blast percentage six months after undergoing an allogeneic transplant who achieved a
sustained complete remission after withdrawal of immunosuppression alone.
Conclusion: This case highlights the importance of a reasonable period of observation after withdrawing
immunosuppression to induce graft-versus-leukemia, and the potential effectiveness of that approach.Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT)
is the only curative treatment for patients with myelodys-
plastic syndrome (MDS). Transplant-related complications
and disease relapse are the major causes of treatment
failure. Therapeutic options to manage disease relapse are
limited and virtually all patients ultimately die of their
disease or from complications of its treatment. Although
withdrawal of immunosuppression is a common initial
therapeutic strategy, its limited record of success com-
monly results in proceeding rapidly to induction
chemotherapy and donor lymphocyte infusion (DLI) in
patients with significant numbers of blasts. Chemo-
therapy, second transplants and DLI are often used but
carry a high degree of morbidity and mortality. Here
we present the case of a patient with relapsed MDS* Correspondence: hamiltb2@ccf.org
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reproduction in any medium, provided the orafter allogeneic HSCT who was successfully treated
with immunosuppression withdrawal.
Case presentation
Our patient was a 41-year-old Caucasian woman who,
four years prior to her presentation to the Cleveland
Clinic, was found on routine blood work to be pancytope-
nic (white blood cell count (WBC) 3300/mm3 with an ab-
solute neutrophil count (ANC) of 1600/mm3, hemoglobin
11.2g/dL, platelet count 104,000/mm3). She noted fatigue
but denied other symptoms. An initial bone marrow biopsy
showed trilineage dyspoiesis with an increase in atypical
myeloblasts (8%), consistent with MDS, categorized as
refractory anemia with excess blasts (RAEB-1). A cytogen-
etic analysis revealed a normal female karyotype. Her initial
score on the International Prognostic Scoring System
(IPSS) was 0.5, or intermediate-1 risk group. She did not
require transfusions and her serum ferritin was 11.3ng/mL.
A subsequent bone marrow biopsy approximately six
months later demonstrated a rising blast percentage to
15%, consistent with MDS RAEB-2. Our patient’s bloodal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stable over the next three years. The blast count on
repeat bone marrows over this time period remained in
the 10% to 15% range. Cytogenetic analysis continued to
demonstrate a normal female karyotype. She remained
asymptomatic and declined therapy, despite the elevated
blast count. She began to develop worsening cytopenias
despite a stable blast percentage on repeat bone marrow
biopsies and she subsequently developed worsening
anemia requiring red blood cell transfusions. As she
became more symptomatic, she agreed to proceed with
allogeneic HSCT from her brother, who had previously
been identified to be human leukocyte antigen (HLA)-
identical. A pretransplant bone marrow biopsy revealed
high-grade MDS with 15% blasts. One month later, she
underwent HSCT following high-dose intravenous
busulfan (12.8mg/kg) and cyclophosphamide (120mg/kg).
Graft-versus-host disease (GVHD) prophylaxis consisted
of cyclosporine and mycophenolate mofetil.
Four weeks after the transplant she developed an
erythematous, pruritic skin rash on her chest, accounting
for approximately 25% of her body surface area. Results
from a skin biopsy confirmed grade 2 acute GVHD. She
also developed nausea and vomiting suggestive of upper
gastrointestinal tract GVHD, although this was not
confirmed on histology. She was treated with 1mg/kg of
prednisone and continued mycophenolate and cyclo-
sporine. Her GVHD symptoms resolved and she was
tapered off prednisone by 18 weeks post-transplantation.
Within this same time frame, it was first noted 125 days
post-transplant that her blood counts had decreased
(WBC, 1450/mm3; ANC, 870/mm3; hemoglobin, 9.7g/dL;
platelet count, 83,000/mm3) although our patient felt well.
An engraftment analysis from her peripheral blood on the
same day, which had previously demonstrated complete
donor leukocyte and T-cell chimerism, demonstrated 3%
of the peripheral blood leukocyte deoxyribonucleic acid
(DNA) of recipient origin and 41% of the T-cell-enriched
fraction containing DNA of recipient origin. Her blood
counts continued to decline. Sixteen days later, approxi-
mately five months after transplantation, her WBC was
940/mm3, ANC 430/mm3, hemoglobin 8.0g/dL and platelet
count 89,000/mm3.
By day 143, a peripheral smear showed a WBC of
1240/mm3, ANC 520/mm3, hemoglobin 10.1g/dL, and a
platelet count of 102,000/mm3 with 1% circulating blasts.
A bone marrow biopsy at this time, now six months after
transplantation, demonstrated relapsed MDS with 12%
blasts. Cytogenetic analysis showed mixed chimerism but
a normal karyotype, 46,XX/46,XY.
A repeat engraftment analysis on day 153 confirmed
increasing recipient chimerism, with 42% of the peripheral
blood leukocyte DNA of recipient origin and 65% of the
T-cell-enriched fraction containing DNA of recipientorigin. Peripheral blood counts on day 153 demonstrated a
WBC of 1700/mm3, ANC 650/mm3, hemoglobin 9.3g/dL,
and a platelet count of 124,000/mm3 with 10% circulating
blasts. Our patient’s immunosuppression (cyclosporine and
mycophenolate mofetil) was stopped day 153 and induction
chemotherapy and DLI were planned.
Our patient was admitted to an outside hospital for
fever and chest pain the following week. Blood counts at
that time revealed a WBC of 8000/mm3 and an ANC of
1500/mm3 with no circulating blasts. She was found to
have pneumonia with an associated parapneumonic
pericardial effusion. She underwent pericardiocentesis
and was transferred to our institution, where she com-
pleted a course of intravenous antibiotics. During her
hospitalization, her WBC and ANC remained in the normal
range with no evidence of circulating blasts. On follow-up,
approximately a month after stopping immunosuppresion,
our patient developed an erythematous, pruritic rash on her
upper and lower extremities, accounting for approximately
50% of her body surface area. Counts at this time dropped,
with a WBC of 98/mm3, hemoglobin 8.3g/dL, and a platelet
count of 5000/mm3. A skin biopsy confirmed grade 2
GVHD. A bone marrow biopsy done the same day, five
weeks after stopping immunosuppression, demonstrated a
hypocellular bone marrow with no evidence of MDS.
Engraftment analysis on day 181 demonstrated only 1% of
peripheral blood leukocyte DNA of recipient origin and no
recipient DNA in the T-cell enriched fraction.
The rash progressed over the next two weeks, becoming
more erythematous and pruritic, and demonstrating
features of both acute and chronic GVHD. Her liver
function tests were also mildly elevated. Prednisone
1mg/kg was initiated and lead to a gradual improvement
of her rash and liver function tests, and she was tapered
off immunosuppression over a six-month period. Her
blood counts normalized by day 209 and she continued to
demonstrate complete donor chimerism. Interestingly, she
developed intermittent neutropenia during her taper, how-
ever this would recover spontaneously and she continued
to demonstrate complete donor chimerism on engraft-
ment studies. Her counts have subsequently completely
normalized. Our patient is currently more than three years
from her allogeneic transplant and more than two and a
half years from stopping immunosuppression. She con-
tinues to do exceedingly well, training for and running in
half-marathons regularly. Her blood counts are normal
and her leukocytes and T-cells are 100% donor.
Discussion
The curative effect of HSCT results not only from the radi-
ation and/or chemotherapy in the conditioning regimen,
but also from a graft-versus-leukemia (GVL) effect exerted
by the donor-derived immune system. The demonstration
that donor T-cells inhibit the growth of leukemia colonies
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model of engraftment and propagation of leukemia in
immunologically susceptible mice, indicate that this im-
munologic effect can be curative [1,2]. The lower incidence
of relapse in patients who develop GVHD supports the
contribution of the donor-derived immune system to the
eradication of malignant cells [3]. The prevention or
moderation of GVHD without loss of a GVL effect remains
a significant and unsolved challenge.
Disease relapse is the most frequent cause of treatment
failure after allogeneic HSCT of MDS. Relapse risk depends
on remission status at the time of transplant, cytogenetic
and molecular abnormalities of the MDS cells, and other
factors. Patients with MDS who relapse after transplant-
ation have dismal prognoses and there is no standard
effective treatment strategy. Options include intensive
chemotherapy and DLI, or second transplants, all of which
are associated with high mortality rates and have achieved
only very limited degrees of success [4]. Novel approaches
to enhance the GVL effect using donor-derived natural
killer cells are being studied [5].
Withdrawal of immunosuppression and DLI has been
moderately successful in the treatment of relapsed
chronic myelogenous leukemia (CML), which is highly
sensitive to the GVL effect. High relapse rates after
T-cell depletion of the allograft in CML transplantation
has been well documented and support the sensitivity
of CML to GVL [3]. Reports of individual patients who
relapse after transplantation but achieve remission
when immunosuppression was stopped and GVHD
flared, and the effectiveness of DLI in achieving long-
term remission in patients who have relapsed provide
further evidence of this.
By contrast, patients with MDS and acute myelogenous
leukemia (AML) who relapse after HSCT are a heteroge-
neous group and there is no single standard approach. Out-
comes with aggressive chemotherapy, DLI or second HSCT
are generally poor [6-8]. The few who benefit are generally
younger patients with good performance status and long
disease-free interval after transplant [4]. Immunosuppres-
sion withdrawal alone has rarely been reported to achieve a
meaningful response after myeloablative transplantation in
MDS or AML [9,10].
Researchers at the MD Anderson Cancer Center
reported durable remissions in a small subset of patients
with MDS or AML who had relapsed after reduced inten-
sity, not myeloablative, regimens and undergone second
HSCT, but dismal outcomes in patients who had their
immunosuppression withdrawn or who received DLI [11].
Only 6.6% of patients achieved a complete remission after
immunosuppression withdrawal; and unlike our patient,
all had less than 10% blasts in their bone marrow and no
circulating blasts. Most of those who did not respond to
immunosuppression withdrawal were treated with furtherchemotherapy or DLI. Results after myeloablative trans-
plant are even less encouraging [9,10].
A large series evaluating immunosuppression withdrawal
demonstrated durable remissions in 84% of patients with
CML, underscoring the strong GVL effect in CML,
whereas only 10% of patients with AML and no advanced
CML or acute lymphoblastic leukemia achieved remissions
at three years [11]. Success was limited to patients who had
sustained complete remission after transplant and who had
low numbers of blasts. Patients with MDS who relapse
shortly after myeloablative transplants with high numbers
of blasts have not achieved sustained remission after with-
drawal of immunosuppression alone and generally proceed
rapidly to more aggressive therapy if appropriate.
The efficacy of DLI in MDS has been evaluated with a
response rate of 14% to 40% [12,13]. DLI has been
effective in inducing long-term remission in a small
subset of patients with MDS; however, responses are
associated with severe GVHD, which can result in
significant transplant-related morbidity and mortality.
The incidence rates of acute and chronic GVHD varied
from 34% to 60% and 14% to 33%, respectively. In one
small series, patients who were higher risk on the IPSS
appeared to have a better response to DLI than those
with lower-intermediate risk IPSS [13]. While low tumor
burden generally is a predictor of response to DLI, MDS is
a clinically and molecularly heterogeneous group, and one
may speculate that the susceptibility to immunologic treat-
ment or GVL effect may be impacted by the cytogenetic
and molecular characteristics of the MDS clone.
The difficulty of determining who may be susceptible to
immunologic treatment or the GVL effect was recently
illustrated by a report of patients who relapsed after
haploidentical transplantation [14]. In five of 17 patients’
mutant leukemic cells, the HLA haplotype that differed
from the donor was lost at relapse due to acquired unipar-
ental disomy of chromosome 6p. Thus, T-cells from the
donor that had recognized and killed the original leukemic
cells no longer recognized the mutant leukemic cells.
Other therapies, such as hypomethylating agents, with or
without DLI or second transplants, also warrant further
investigation in this setting. A recent report demonstrated
the safety and efficacy of azacitidine as a treatment for
minimal residual disease [15]. Twenty patients with de-
creasing donor chimerism were treated with four cycles of
azacitidine and 80% of these patients responded with either
increasing donor chimerism or stabilization in the absence
of relapse. Although relapse eventually occurred in 65% of
these patients, time to relapse was significantly delayed.
There remains significant variability in regards to
long-term disease control in patients with MDS who
relapse after transplant. Several factors are involved,
including the disease status at time of transplant, remission
duration, disease tempo at time of relapse, molecular and
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comorbidities, including infections and active GVHD, also
play an important role in determining subsequent therapy.
Our case illustrates that immunosuppression withdrawal
remains a valid and efficacious therapeutic modality in
MDS relapse after allogeneic transplant. Although our pa-
tient had a higher blast percentage than has generally been
associated with withdrawal of immunosuppression being
effective, her disease was relatively slow in its evolution
both initially and at relapse, and thus may have allowed for
the adequate time required for immunosuppression with-
drawal to work. Cytogenetic and molecular risk may have
further played a role in disease kinetics as well as sensitivity
of our patient’s MDS clone to immune manipulation.
Conclusion
Although the approach to relapsed MDS or AML after
allogeneic transplant remains challenging, our case high-
lights the importance of at least four weeks’ observation for
GVHD or hematologic improvement following immuno-
suppression withdrawal. Even in patients who have been
identified as having factors that would predict poor response
to immunosuppression withdrawal, it should be considered
as an initial tactic in cases of relapsed disease where an im-
mediate response is not required. Unnecessary toxic chemo-
therapy and severe GVHD after DLI, both of which achieve
only limited success, can be avoided with this approach.
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